The size of the Europe Infectious Disease Therapeutics Market is predicted to be worth USD 40.97 billion by 2027 from USD 29.24 billion in 2022, growing at a CAGR of 6.98% during the forecast period.
Rising investments to discover new medications to treat infectious diseases, Government and private organizations are heavily investing in the healthcare sector, and an increase in the number of efforts to promote awareness about these disorders are projected to drive the Europe Infectious Disease Therapeutics market during the forecast period. Infectious disease treatments are being used more frequently as the prevalence of infectious diseases rises. Other factors driving the growth of the infectious diseases therapeutics market include the increased usage of direct-acting antivirals, an increase in the elderly population, and rising healthcare spending. One of the key factors for market growth during the forecast period is the rising incidence of infectious illnesses such as tuberculosis, AIDS, and others throughout the region.
Additionally, infectious disease treatments are likely to see a rise in demand as more patents expire and generic medicines enter the market due to their low pricing. The availability of reimbursement for diagnosis and treatment of various infections and free medicine distribution by manufacturers in areas where these diseases are prevalent will likely propel the European Infectious Disease Therapeutics market further. The emergence of interferon-free regimens and increased awareness programs are two trends in the infectious diseases treatments industry. Advances in the rapid diagnosis of many infectious diseases, which allow for earlier and faster diagnosis, have a significant influence on the medical result of disease treatment. Advanced technologies utilized in fast diagnostics of infectious diseases, such as lateral flow, agglutination tests, and solid phase, are combined with novel characteristics such as mobility of portable devices to provide a viable approach.
During the forecast period, the Europe Infectious Disease Therapeutics market is likely to be restrained by a low penetration rate of anti-infective and the availability of a significant number of counterfeit medications. In this nation, limited treatment adoption and low per capita healthcare expenditure may limit market growth throughout the forecast period. Furthermore, lack of awareness regarding treatments for disorders, poor treatment adoption, and lack of funding for certain infectious illnesses are likely to limit the growth of the infectious disease therapeutics market during the forecast period.
Generic erosion is one of the key issues restricting the Europe Infectious Disease Therapeutics market's growth. The infectious diseases therapeutics industry may face a challenge when patents on infectious disease medicines expire.
This research report on the European Infectious Disease Therapeutics Market has been segmented & sub-segmented into the following categories:
By Mode of Treatment:
By Target Organism:
By Infection type:
By Distribution Channels:
Europe is the world's second-largest market for infectious disease therapeutics. The European market is driven by high healthcare spending, government funding for research and development, and a large patient population. In the worldwide infectious diseases therapeutics market, Europe is anticipated to develop rapidly over the next five years. The rising need for efficient and quick diagnostic testing, an increase in the number of methods used by market participants to extend their geographic reach in this area, and government organizations’ involvement in reducing illness burden are likely to fuel market growth.
KEY MARKET PLAYERS:
Companies that are playing an influential role in the European Infectious disease Therapeutics Market profiled in this report are F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck & Co, Pfizer, Achillion Pharmaceuticals, Novartis, AbbVie, Astellas Pharma, AstraZeneca, Auritec Pharmaceuticals, Bayer, Bristol-Myers Squibb, Chimerix Pharmaceuticals, Cubist, Eli Lilly, Isis Pharmaceuticals, Mitsubishi Tanabe Pharma, pSivida, Sanofi.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com